Shares of Fulcrum Therapeutics jumped after Pfizer said it is withdrawing all lots of its sickle cell disease drug Oxbryta and the European Medicines Agency recommended to suspend its marketing authorization. The stock was up 26% to $4.38 on Thursday, on pace for the largest percent increase since August 2023.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.